Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias
FILTRAR POR:
507 ARTÍCULOS , VIENDO DEL 1 AL 15
APOE ɛ2 is associated with white matter hyperintensity volume in CADASIL
Gesierich B, Opherk C, Rosand J, Gonik M, Malik R, Jouvent E, Hervé D, Adib-Samii P, Bevan S, Pianese L, Silvestri S, Dotti MT, De Stefano N, van der Grond J, Boon EM, Pescini F, Rost N, Pantoni L, Oberstein SA, Federico A, Ragno M, Markus HS, Tournier-Lasserve E, Chabriat H, Dichgans M, Duering M, Ewers M.
J Cereb Blood Flow Metab. 2016 Jan;36(1):199-203. doi: 10.1038/jcbfm.2015.85.
From Subjective Cognitive Complaints to Dementia: Who is at Risk?: A Systematic Review
Mendonça MD, Alves L, Bugalho P.
Am J Alzheimers Dis Other Demen. 2016 Mar;31(2):105-14. doi: 10.1177/1533317515592331.
The neuropathology and cerebrovascular mechanisms of dementia
Raz L, Knoefel J, Bhaskar K.
J Cereb Blood Flow Metab. 2016 Jan;36(1):172-86. doi: 10.1038/jcbfm.2015.164.
Weick JP, Kang H, Bonadurer GF 3rd, Bhattacharyya A.
Methods Mol Biol. 2016;1303:247-65. doi: 10.1007/978-1-4939-2627-5_15.
The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease
Iulita MF, Cuello AC.
Curr Alzheimer Res. 2016;13(1):53-67. doi: 10.2174/1567205012666150921100030.
Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy
Phillips C, Fahimi A, Das D, Mojabi FS, Ponnusamy R, Salehi A.
Curr Alzheimer Res. 2016;13(1):68-83. doi: 10.2174/1567205012666150921095924.
Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
Hamlett ED, Boger HA, Ledreux A, Kelley CM, Mufson EJ, Falangola MF, Guilfoyle DN, Nixon RA, Patterson D, Duval N, Granholm AC.
Curr Alzheimer Res. 2016;13(1):35-52. doi: 10.2174/1567205012666150921095505.
[Cognitive rehabilitation in early stage Alzheimer's disease]
Kasper E, Thöne-Otto A, Bürger K, Schröder SG, Hoffmann W, Schneider W, Teipel S.
Nervenarzt. 2016 Jul;87(7):708-18. doi: 10.1007/s00115-015-4426-2.
Giulietti A, Vignini A, Nanetti L, Mazzanti L, Di Primio R, Salvolini E.
Curr Neuropharmacol. 2016;14(2):177-90. doi: 10.2174/1570159x13666150928155321.
Entorhinal cortex: a good biomarker of mild cognitive impairment and mild Alzheimer's disease
Zhou M, Zhang F, Zhao L, Qian J, Dong C.
Rev Neurosci. 2016 Feb;27(2):185-95. doi: 10.1515/revneuro-2015-0019.
Predictive factors for disease progression in patients with early-onset Alzheimer's disease
Yoon B, Shim YS, Park HK, Park SA, Choi SH, Yang DW.
J Alzheimers Dis. 2016;49(1):85-91. doi: 10.3233/JAD-150462.
The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective
Salehi A, Ashford JW, Mufson EJ.
Curr Alzheimer Res. 2016;13(1):2-6. doi: 10.2174/1567205012999151021102914.
Coleman KK, Coleman BL, MacKinley JD, Pasternak SH, Finger EC.
Alzheimer Dis Assoc Disord. 2016 Jul-Sep;30(3):258-63. doi: 10.1097/WAD.0000000000000119.
Recent Updates on the Association Between Alzheimer's Disease and Vascular Dementia
Ashraf GM, Chibber S, Mohammad, Zaidi SK, Tabrez S, Ahmad A, Shakil S, Mushtaq G, Baeesa SS, Kamal MA.
Med Chem. 2016;12(3):226-37. doi: 10.2174/1573406411666151030111820.
Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia
Graff-Radford J, Josephs KA, Parisi JE, Dickson DW, Giannini C, Boeve BF.
JAMA Neurol. 2016 Jan;73(1):123-5. doi: 10.1001/jamaneurol.2015.2711.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.